From the ∗Division of Radiology, German Cancer Research Center, Heidelberg, Germany
†Medical Faculty, University of Heidelberg, Heidelberg, Germany
‡Division of Medical Image Computing, German Cancer Research Center, Heidelberg, Germany
§Department of Biomedical Engineering, Faculty of Electrical Engineering and Communication, Brno University of Technology, Brno, Czech Republic
∥Diagnostic and Interventional Radiology
¶Department of Medicine V, Multiple Myeloma Section, Heidelberg University Hospital, Heidelberg, Germany
#National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
∗∗Institute for AI in Medicine, University Medicine Essen, Essen, Germany
††Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
‡‡Department of Diagnostic and Interventional Radiology, Experimental Radiology Section, University Hospital Ulm, Ulm, Germany.
Received for publication June 18, 2022; and accepted for publication, after revision, August 13, 2022.
Conflicts of interest and sources of funding: This study did not receive specific funding. The following relationships are disclosed: M.W., F.B., A.K., J.C., M.G., L.T.R., P.N., F.T.K., T.N., N.W., J.K., T.F.W., S.D., K.M.-H. and M.Gö. have nothing to declare. R.G. declared receiving payment for working for HQ Imaging. S.S. reported receiving travel grants or honoraria for presentations from Celgene, BMS, Janssen, Takeda, and Amgen. H.G. reported receiving grants and/or provision of Investigational Medicinal Product from Amgen, Array Biopharma/Pfizer, BMS/Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, Sanofi, receiving Research Support: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte Corporation, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme (MSD), MorphoSys AG, Pfizer, Sanofi, Takeda, Novartis, being on the Advisory Boards of Amgen, BMS, Janssen, Sanofi, Adaptive Biotechnology and receiving Honoraria from Amgen, BMS, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. H.-P.S. declares receiving consulting fee or honorarium from Siemens, Curagita, Profound, and Bayer; declares receiving travel support from Siemens, Curagita, Profound, and Bayer; is a board member of Curagita; provides consultancy for Curagita and Bayer; declares receiving grants/grants pending from BMBF, Deutsche Krebshilfe, Dietmar-Hopp-Stiftung, and Roland-Ernst-Stiftung; and declares receiving payment for lectures from Siemens, Curagita, Profound, and Bayer.
Correspondence to: Markus Wennmann, MD, Division of Radiology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. E-mail: [email protected].
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.investigativeradiology.com).